AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04591314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: The intervention by neurofeedback (NF) will consist in providing the subjects with a feedback on their EEG Theta / Beta activity in real time Each subject will perform 8 sessions of neurofeedback (1h30 / session, 40 min of effective training by neurofeedback) at an average rate of 1 to 2 sessions per week.
Study NCT05027646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sancuso - Part 1
Description: Part 1 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
Study NCT05027646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sancuso - Part 2
Description: Part 2 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
Study NCT06242665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low UPF Meals (Study Provided)
Description: Meals provided through delivery service
Study NCT06242665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low UPF Nutritional Guidance
Description: Self-guided instructions from study team.
Study NCT04789733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tight pressure management
Description: Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg, delayed resumption of chronic antihypertensive medications, and a target ward MAP ≥80 mmHg (tight pressure management)
Study NCT04789733 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine pressure management
Description: Routine intraoperative blood pressure management and immediate restart of antihypertensive medications.
Study NCT04408924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT05319574 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic body radiation therapy delivered with a fixed dose (8Gy) in 3 daily fractions 1-7 days before the first cycle of immunochemotherapy
Study NCT05319574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg q3w for two cycles administrated concurrently with chemotherapy
Study NCT05647252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire for study participants immediately after the decolonization
Description: A questionnaire in GErman language will be handed out to decolonized patients with five questions: Practical difficulties of decolonization, the completeness of scheduled decolonization actions, all adverse events during decolonization and surgery, and two questions regarding the comprehension of the science (indication for decolonization, potential benefit expected in the individual case).~The questionnaire is handmade and validated by the Investigators.
Study NCT06304896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol 6.25 mg oral tablets. Prescribed: Twice daily PO with 200 mL of water.
Study NCT06304896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 2.5 mg oral capsules. Prescribed: Once daily PO with 200 mL of water.
Study NCT06304896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg oral tablets. Prescribed: Once daily PO with 200 mL of water.
Study NCT06304896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 0.6 mg oral tablets/capsules. Prescribed: Once daily PO with 200 mL of water.
Study NCT06304896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules. Prescribed: Once daily PO with 200 mL of water.
Study NCT05768139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant
Study NCT05768139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib
Study NCT05768139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib
Study NCT06642935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Totally implantable cochlear Implant
Description: Totally implantable cochlear Implant
Study NCT05703672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate
Description: 0.5 mg once daily for days 1-3, 0.5mg twice daily for days 4-7 and 1.0 mg twice daily from day 8 through week 12.
Study NCT05703672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One pill (white) once daily for days 1-3, one pill (white) twice daily for days 4-7 and one pill (blue) twice daily from day 8 through week 12.
Study NCT05703672 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electronic cigarette
Description: Nicotine salt pod based e-cigarette in 5% nicotine
Study NCT05703672 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electronic cigarette
Description: Nicotine salt pod based e-cigarette in 5% nicotine
Study NCT05703672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic cigarette
Description: Nicotine salt pod based e-cigarette in 5% nicotine
Study NCT04632303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Palliative Care
Description: Baseline palliative care visit Palliative care visits/calls at least every 4 weeks throughout life and additionally upon request Referral to exercise training Referral to nutritional specialist
Study NCT05851326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Sonodyn
Description: Sonodyn emits ultrasound, electrical and magnetic stimulation signals with a pre-defined, fixed set of parameters for each of the independently operated power sources.
Study NCT05851326 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Non-functional Sonodyn device that cannot convey any energy signals to the device output, however, looks and behaves fully identical as the active Sonodyn device.
Study NCT05114538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reciprocal Imitation Training
Description: RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and IJA during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal skills. It is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by parents and siblings.
Study NCT05373940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD implantation
Description: This group will undergo an ICD implantation (type and manufacturer at the discretion of the local investigator) in addition to heart failure medical therapy optimization.~Patients of the HFOT+ICD group will be scheduled for ICD implantation.
Study NCT05373940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No ICD implantation
Description: Patients of the HFOT alone group will not undergo ICD implantation (except if they develop sustained ventricular arrhythmias and fulfil for secondary prevention ICD implantation), and continue with medical therapy optimization only.
Study NCT05944224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH4336
Description: SPH4336 Tablets ：Orally, 400mg once a day ; 28 days/cycle
Study NCT05944224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Intravenous infusion, 6mg/Kg,28 days/cycle
Study NCT06497569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietitian Consultation
Description: Participants will meet with a dietitian who will provide individualized nutrition counseling and dietary goals for calorie and protein intake.~Bi-weekly, 30-minute dietitian telehealth visits will be conducted via ZOOM videoconferencing at the pre-intervention baseline visit, monthly during the intervention period (up to 90 days) and at the 4 and 6 month timepoints post-intervention.
Study NCT06497569 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietitian Consultation
Description: Participants will meet with a dietitian who will provide individualized nutrition counseling and dietary goals for calorie and protein intake.~Bi-weekly, 30-minute dietitian telehealth visits will be conducted via ZOOM videoconferencing at the pre-intervention baseline visit, monthly during the intervention period (up to 90 days) and at the 4 and 6 month timepoints post-intervention.
Study NCT06497569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Surveys will be conducted using the PG-SGA short form19-21 and a brief symptom assessment tool that captures additional nutrition-impact symptoms not captured by the PG-SGA (e.g., swallowing difficulty) measured by the FACT Esophageal and Gastric Cancer scales and the FAACT anorexia/cachexia scales 22,23 through REDCap.~Surveys are completed at the pre-intervention baseline visit and monthly during the intervention period prior to the dietitian visits (up to 90 days), and at the 4 and 6 month timepoints post-intervention.
Study NCT06497569 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: Surveys will be conducted using the PG-SGA short form19-21 and a brief symptom assessment tool that captures additional nutrition-impact symptoms not captured by the PG-SGA (e.g., swallowing difficulty) measured by the FACT Esophageal and Gastric Cancer scales and the FAACT anorexia/cachexia scales 22,23 through REDCap.~Surveys are completed at the pre-intervention baseline visit and monthly during the intervention period prior to the dietitian visits (up to 90 days), and at the 4 and 6 month timepoints post-intervention.
Study NCT06497569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit Data Collection
Description: Participants will log food intake while sharing their data with a dietitian during the 30-minute dietitian telehealth visits at the pre-intervention baseline visit, monthly during the intervention period (up to 90 days) and at the 4 and 6 month timepoints post-intervention.
Study NCT06497569 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral to Dietitian
Description: Usual Care condition referral to a dietitian based on physician discretion.
Study NCT06497569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Determinants of Health Survey (SDOH)
Description: Participants will complete a SDOH Survey that captures individual-level factors (insurance type, preferred language, educational attainment, annual household income, digital health literacy, financial toxicity, and self-reported barriers to care \[e.g., transportation\]) and structural-level factors (neighborhood disadvantage, rural residence).~Digital health literacy will be measured using the validated eHEALS scale, an 8-item measure assessing confidence with finding, evaluating, and applying electronic information to inform health decision-making (score ≤ 30 indicates low literacy).
Study NCT05894239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Participants will receive an inavolisib tablet to be taken orally (PO), once a day (QD), on Days 1-21 of each 21-day cycle, beginning on Day (D) 1 of Cycle (C) 1 of maintenance treatment.
Study NCT05894239 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Phesgo
Description: Phesgo will be administered to participants subcutaneously every 3 weeks (Q3W) on D1 of each 21-day cycle.
Study NCT05755854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic γ9δ2 T Cells
Description: dose escalation (3+3) : dose 1 (5 × 10\^7cells/kg) ,dose 2 (1 × 10\^8 cells/kg) ,dose 3 (2 × 10\^8cells/kg)
Study NCT05755854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous fludarabine on days-5 and -4,the infusion dose is adjusted according to the subject's condition
Study NCT05755854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous cyclophosphamide on days -5、-4、and -3, the infusion dose is adjusted according to the subject's condition
Study NCT05755854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoredronic acid
Description: Intravenous zoredronic acid 50ug/kg 24 hours before cell infusion（or according to the dosage of the instruction）（If applicable）
Study NCT06465979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Manipulation
Description: The acoustic properties of speech sounds will be modified in two main ways. The first way is to introduce gradual changes to the perceived articulation of the target speech sound, such as changing from sh to s by various types of signal processing and filtering. The second type of change is to modify acoustic properties of the sounds that immediately precede the target speech sound, such as changing the speaking rate or its frequencies composition.
Study NCT05841160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam Hydrochloride
Description: oral tablets
Study NCT05841160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: oral tablet
Study NCT06242665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low UPF Snacks (Study Provided)
Description: Low UPF snacks provided to participant
Study NCT05841160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral tablet
Study NCT05841160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study NCT05490069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iCBT-based EMI
Description: Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and real-time chat-based support messages, delivered according to participants' preferences.
Study NCT06036979 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral plane block
Description: With the patients are placed in the sitting position, counting down from C7 spinous process, a high frequency linear ultrasound probe is placed on the spinous process in the parasagittal plane at T5 level and then is slided laterally 2-3 cm to make the transverse processes clearly visualized . Under aseptic conditions, a 22-gauge block needle (50mm, B.Braun, Germany) is inserted using in-plane technique toward the paravertebral space, immediately above the pleura and below the superior costotransverse ligament. The position of the needle is confirmed by the descent of the pleura when injecting 2 to 3 ml of saline solution for hydrolocalization. Then 0.3ml/kg of bupivacaine 0.25% is injected under ultrasound guidance. Block success is defined as reduced sensitivity to cold and pinprick stimuli as compared with the contralateral side 20 minutes after local anesthetic injection.
Study NCT06036979 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: With the patients are placed in the sitting position, counting down from C7 spinous process, a high frequency linear ultrasound probe is placed on the spinous process in the parasagittal plane at T5 level and then is slided laterally 2-3 cm to make the tips of the transverse processes clearly visualized . The following muscles seen from superficial to deep layer are trapezius, rhomboid major and erector spinae muscles. Under aseptic conditions, a 22-gauge block needle (50mm, B.Braun, Germany) is inserted using in-plane technique to reach the interfascial plane between the transverse process and the erector spinae muscle. Following confirmation of the accurate position of the needle tip with 3-5 ml normal saline solution, 0.3ml/kg of bupivacaine 0.25% is injected under ultrasound guidance. Block success is defined as reduced sensitivity to cold and pinprick stimuli as compared with the contralateral side 20 minutes after local anesthetic injection.
Study NCT06036979 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous morphine, ketorlac and paracetamol
Description: • In the control group only we add 10mg intravenous morphine, 30 mg intravenous ketorlac and 1 gm intravenous paracetamol for analgesia.
Study NCT06168721 — intervention group
Intervention type: OTHER
Intervention: Expert survey
Description: The expert group will participate in a two-round survey using the Delphi method. The first round aims to assess the relevance of the proposed ICF categories and to identify missing concepts. The second round will aim to confirm the appropriateness of including the selected categories in the ICF core set. Each round will last 3 weeks and the experts will be provided with feedback on the results obtained.
Study NCT06472505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polyglycolic acid(Neoveil)
Description: This study plans to enroll patients with pituitary tumors who need to undergo surgical treatment according to current routine medical standards. After the tumor tissue is removed, the integrity of the spider web or skull base will be thoroughly checked by endoscopy during the operation to confirm whether there is any cerebrospinal fluid leakage. At the end of the operation, use a 100\*50\*0.15mm, green sheet-like Navi tissue repair patch, cut it aseptically to fit the size of the defect for repair (the common case is 2\*3.5cm defect), and place it on the spider web or skull base Tissue repair at the surgical site to prevent cerebrospinal fluid leakage.
Study NCT04104477 — intervention group
Intervention type: OTHER
Intervention: Range of Motion Tasks
Description: Participants will perform range of motion (thumb only) to evaluate fine and gross motor function.
Study NCT04652063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine
Description: Osteopathic evaluation and treatment (gentle touch according to published protocols) will take about 15 - 20 minutes, and will be performed every 7 - 10 days during the infant's NICU stay once they reach at minimum of at least 28 weeks corrected gestational age and until they reach 36 weeks corrected gestational age.
Study NCT06190210 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: electroencephalography
Description: Pre-, per- and postoperative electroencephalography
Study NCT06190210 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Near-Infrared Spectroscopy
Description: Pre-, Per- and Postoperative near-infrared spectroscopy returning regional cerebral oxygen saturation
Study NCT06190210 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: neuronal cell-free DNA
Description: CfDNA which is characterized based on methylation patterns to determine the tissue of origin
Study NCT05295524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaftrio utilization in real life
Description: daily utilization of PHEAL-CR-K application at home and VOC (volatile organic compound) measure of exhaled air for a group of the patients
Study NCT06076109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prone position
Description: Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the prone position.
Study NCT06076109 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the supine position with the head of the bed between 30-60º.
Study NCT05141474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEXTGEN-TIL
Description: NEXTGEN-TIL product is a cellular investigational product comprising a live cell suspension of autologous tumor-infiltrating lymphocytes derived from the patient's own tumor.~Each dose contains at least 5 x 10\^8 total viable lymphocytes, and a maximum of 1.11x10\^11. It will be administered IV on Day 0 (24h after the last dose of Fludarabine).
Study NCT05141474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-myeloablative Lymphodepletion (NMA-LD) Regimen
Description: Patients will receive a NMA-LD chemotherapy based on Cyclophosphamide 60 mg/kg IV (once daily on Days -5 and -4) and Fludarabine 25 mg/m2 IV (once daily on Days -5 to -1).
Study NCT05141474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Patients will receive sequential doses of 720,000 IU/kg IV IL-2 every 8-24 hours depending on patient tolerance. It will be administered on Days 0 to 2, starting between 3 and 24 hours after the completion of NEXTGEN-TIL infusion.~IL-2 doses may be skipped in case of toxicity. If 2 sequential doses or more than 2 non-sequential doses of IL-2 are skipped due to patient intolerance or the discretion of the investigator, IL-2 administration must be stopped.
Study NCT06581081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Senl_B19 autologous CAR-T (S1904) treatment
Description: Subjects enrolled in this study will first receive Senl_B19 autologous CAR-T (S1904) treatment.
Study NCT06581081 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Senl_B19 autologous CAR-T (S1904) treatment
Description: Subjects enrolled in this study will first receive Senl_B19 autologous CAR-T (S1904) treatment.
Study NCT05894239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phesgo
Description: Phesgo will be administered to participants subcutaneously every 3 weeks (Q3W) on D1 of each 21-day cycle.
Study NCT05894239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phesgo
Description: Phesgo will be administered to participants subcutaneously every 3 weeks (Q3W) on D1 of each 21-day cycle.
Study NCT05894239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Inavolisib-matching tablet taken PO QD on Days 1-21 of each 21-day cycle, beginning on D1 C1 of maintenance treatment.